Please login to the form below

insulin degludec

This page shows the latest insulin degludec news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk preps for speedy oral GLP-1 drug filing

Group sales barely moved in 2018 compared to the prior year, coming in at 112bn krone, with the GLP-1 portfolio’s growth offsetting declines in insulin products. ... 10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a

Latest news

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Xultophy (insulin degludec and liraglutide) which rocketed more than 150% in the first six months of the year to 720m krone. ... 80bn krone on price reductions, competition from generic long-acting insulins including insulin glargine, and cannibalisation
Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Victoza’s performance meant that Novo Nordisk was able to weather the pressure in the insulins market, which kept its overall insulin sales flat at DKK 14.66bn. ... This was despite growth for new long-acting insulin Tresiba (insulin degludec), which
CHMP backs first-line use for AZ’s Tagrisso in lung cancer

insulin degludec/liraglutide).
Novo seeks to strengthen Tresiba label in US

Studies find insulin degludec advantage over insulin glargine. Novo Nordisk has filed new data to the FDA showing its long-acting insulin Tresiba is less likely to cause low blood sugar ... The Danish drugmaker wants the results of the DEVOTE trial -
Sanofi wins EU approval for new diabetes combination Suliqua

The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is ... same day as rival therapy Xultophy, Novo

More from news
Approximately 12 fully matching, plus 55 partially matching documents found.

Latest Intelligence

Interview: Peter Meeus, Novo Nordisk

Vice president sales and marketing, Novo Nordisk. International marketing manager insulin analogues, Novo Nordisk. ... Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Management: Competitive Salary Offered

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Principal Medical Writer: Varies on experience

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

PMHub

Add my company

Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...